Recent share performance and business profile

Sabra Health Care REIT (SBRA) has been on many investors’ radars after the stock declined around 3% year to date, with additional weakness over the past month and past 3 months.

At a last close of US$18.57, Sabra is a roughly US$4.8b real estate investment trust that owns and invests in healthcare properties across the United States and Canada through a self-administered, self-managed structure.

Recent share price momentum has softened, with the stock down 2.5% over the last day and around 10.7% over the past week. In contrast, longer term total shareholder returns of 12.9% over one year and 98.2% over three years highlight how different short and long timeframes can look.

If this shift in sentiment has you thinking about where else to put fresh capital to work, it could be a good moment to scan 33 power grid technology and infrastructure stocks

With Sabra posting annual revenue of US$815.7m and net income of US$156.2m, along with an indicated intrinsic discount of 64.6%, the key question is whether the recent share pullback signals an undervalued stock or whether the market is already pricing in future growth.

Most Popular Narrative: 18.2% Undervalued

Sabra Health Care REIT’s most followed narrative pegs fair value at US$22.69 per share, comfortably above the last close at US$18.57. This puts the recent pullback in a different light.

The limited new development of senior housing driven by elevated construction and financing costs has created a supply demand imbalance in key markets, giving Sabra pricing power for rent increases and occupancy gains, resulting in expanding margins and boosting net operating income.

Want to see how this story is built numerically? Revenue, earnings and margins are all pushed forward on a detailed timeline. The path to that higher fair value rests on layered assumptions about growth, profitability and valuation multiples that are anything but generic.

Result: Fair Value of $22.69 (UNDERVALUED)

However, this hinges on smooth operator transitions and supportive reimbursement trends, and setbacks on either front could quickly weaken rent coverage and confidence in cash flow.

Another Way To Look At The Price

The narrative leans heavily on future cash flows, yet the current P/E of about 30x tells a more cautious story. It sits above the Global Health Care REITs average of 21.5x, but below a fair ratio estimate of 39.1x. This points to both upside potential and valuation risk if expectations shift.

For a closer read on what this gap could mean in practice for investors weighing upside against downside, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment clearly split between concern and optimism, this is a good moment to move quickly, examine the underlying data yourself, and shape your own view by weighing the 4 key rewards and 2 important warning signs

Looking for more investment ideas?

If Sabra has sharpened your thinking, do not stop here. Widen your search now so you are not late to the next opportunity.

• Target potential mispricing by scanning companies on 46 high quality undervalued stocks that combine solid fundamentals with attractive valuations.
• Lock in income-focused ideas by reviewing stocks in the 11 dividend fortresses that may suit a yield oriented portfolio.
• Dial down portfolio stress by checking resilient companies flagged in the 63 resilient stocks with low risk scores with steadier profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.